Karyopharm Prices Upsized IPO
Intermune Pads Cash with $84.5M to Widen ‘PANORAMA’ for Esbriet
By Jennifer Boggs
Wednesday, November 6, 2013
On the heels of better-than-expected third quarter sales for idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) in Europe, Intermune Inc. priced a public offering to raise $84.5 million to help fund additional studies of Esbriet, including the pivotal trial needed for U.S. approval of the drug and studies to expand its use in IPF and other indications.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.